title: Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
abstract: Collecting duct carcinoma (CDC) is a rare and aggressive renal cell carcinoma (RCC) with extremely poor prognosis, which has been shown to have a poor response to several kinds of systemic therapy. Targeted agents have greatly changed the therapeutic landscape in advanced RCC. Nonetheless, patients with CDC are always excluded from the prospective trials with targeted therapies due to its rarity. We present a case of metastatic CDC that responded favorably to the multiple tyrosine kinase inhibitor, sorafenib, achieving a partial response in both lungs and retroperitoneal lymph nodes metastases. We also reviewed the limited number of reports of metastatic CDC treated with targeted agents and found that 33.33 % (4/12) of patients had favorable clinical activity. These suggest that targeted therapy should be considered for the treatment of metastatic CDC and its prospective evaluation is encouraged.
authors.affiliation: Department of Urology, West China Hospital, Sichuan University, Guoxue Xiang 37, Chengdu, Sichuan, People's Republic of China.
authors.forename: Rui-ning
authors.initials: RN
authors.lastname: Zhao
authors.forename: Li-hong
authors.initials: LH
authors.lastname: Nie
authors.forename: Rui
authors.initials: R
authors.lastname: Gong
authors.forename: Jian-zhong
authors.initials: JZ
authors.lastname: Wang
authors.forename: Romel
authors.initials: R
authors.lastname: Wazir
authors.forename: Liang-ren
authors.initials: LR
authors.lastname: Liu
authors.forename: Tu-run
authors.initials: TR
authors.lastname: Song
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001707:Biopsy, Needle; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D018450:Disease Progression; D016503:Drug Delivery Systems / Q000379:methods*; D017809:Fatal Outcome; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D007685:Kidney Tubules, Collecting / Q000473:pathology*; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D035583:Rare Diseases; D018570:Risk Assessment; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib